Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103-Reference-Cited by-同舟云学术

Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103

Published:2024 Issue:13 Volume:53 Page:6031-6040
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Happl B.¹²³,Balber T.¹²⁴^ORCID,Heffeter P.⁵⁶^ORCID,Denk C.⁷⁸^ORCID,Welch J. M.⁸,Köster U.⁹^ORCID,Alliot C.¹⁰¹¹,Bonraisin A.-C.¹⁰,Brandt M.¹²⁴^ORCID,Haddad F.¹⁰¹²^ORCID,Sterba J. H.⁸^ORCID,Kandioller W.³⁶^ORCID,Mitterhauser M.¹²³⁴,Hacker M.²^ORCID,Keppler B. K.³⁶^ORCID,Mindt T. L.¹²³⁴^ORCID

Affiliation:

1. Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

2. Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

3. Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Josef-Holaubek-Platz 2 and Währinger Straße 42, 1090 Vienna, Austria

4. Joint Applied Medicinal Radiochemistry Facility of the University of Vienna and the Medical University of Vienna, Vienna, Austria

5. Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8A, 1090 Vienna, Austria

6. Research cluster “Translational Cancer Therapy Research”, Währinger Straße 42, 1090 Vienna, Austria

7. Institute of Applied Synthetic Chemistry, Technische Universität (TU) Wien, Getreidemarkt 9, 1060 Vienna, Austria

8. Center for Labelling and Isotope Production, TRIGA Center Atominstitut, TU Wien, Vienna, Austria

9. Institut Laue-Langevin, 71 avenue des Martyrs, 38042 Grenoble Cedex 9, France

10. GIP ARRONAX, 1 rue Aronnax, CS10112, 44817, Saint-Herblain Cedex, France

11. CRCI2NA, Inserm/CNRS/Nantes Université, 8 quai Moncousu, 44007, Nantes Cedex 1, France

12. Laboratoire Subatech, UMR 6457, IMT Nantes Atlantique/CNRS-IN2P3/Nantes Université, 4 Rue A. Kastler, BP 20722, 44307, Nantes Cedex 3, France

Abstract

Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.

Funder

Institut National des Sciences de l'Univers, Centre National de la Recherche Scientifique

Institut National de la Santé et de la Recherche Médicale

Conseil Régional des Pays de la Loire

European Commission

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/DT/D4DT00118D

Reference42 articles.

1. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

2. D.Kreutz , C.Gerner and S. M.Meier-Menches , in Metal-based Anticancer Agents , ed. A. Casini , A. Vessières and S. M. Meier-Menches , The Royal Society of Chemistry , London , 2019 , 10 , 246–270

3. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies

4. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ru(ii)–arene azole complexes as anti-amyloid-β agents;Dalton Transactions;2024